
Silence Therapeutics plc
77
Recent developments include Q3 2026 financial results reporting, clinical trial progress with Divesiran, a public offering, and significant stock price movements related to acquisition activity and market sentiment.
- Silence Therapeutics reported third quarter 2026 financial results including a net loss of $12.426 million and EPS of -$0.08 per share for the period ending September 30, 2026 [N1][S2].
- The company’s lead RNAi therapeutic, Divesiran, met its primary goal in a Phase 2 polycythemia vera study and is preparing for a Phase 3 trial [N7][N8].
- Silence Therapeutics announced a $150 million public offering in American Depositary Shares in August 2026 [N1].
- The stock surged 126% following an acquisition deal with Merck KGaA in October 2026 [N4].
- The stock experienced a 28.8% decline over four weeks in mid-October 2026, with analysis suggesting a potential trend reversal [N5].
- Wall Street analysts have discussed significant upside potential for the stock, with various articles highlighting possible rallies and gains [N2][N6].
- The board and senior IT leadership maintain active cybersecurity risk management processes, including incident response escalation and audit committee oversight [S1].
Silence Therapeutics plc focuses on developing RNA interference (RNAi) therapeutics targeting serious diseases. The company’s lead candidate, Divesiran, has advanced through clinical trials, achieving Phase 2 goals in polycythemia vera and preparing for Phase 3 studies. Financial disclosures as of Q3 2026 show a net loss and strong liquidity, supported by a recent public offering. The company’s governance includes active oversight of cybersecurity risks. Recent stock price movements reflect clinical and acquisition developments.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Silence Therapeutics plc is a biopharmaceutical company developing RNAi therapeutics, with recent clinical progress on its lead candidate Divesiran and significant liquidity as of Q3 2026. The company’s stock has experienced notable volatility related to acquisition activity and clinical milestones. Cybersecurity risk management is overseen by the board and senior IT leadership [N1][N4][S1][S2].
Clinical progress with Divesiran meeting Phase 2 endpoints and advancing to Phase 3 trials demonstrates execution capability. The company’s strong liquidity position supports ongoing development activities. Acquisition interest, such as the Merck KGaA deal, indicates external validation of its technology and pipeline value. Active risk management and governance structures enhance operational resilience.
The company continues to report net losses, reflecting the high costs and risks inherent in clinical development. Stock price volatility indicates market sensitivity to clinical and acquisition news, which may affect investor sentiment. Cybersecurity risks pose potential operational and reputational challenges. The absence of disclosed commercial revenues limits near-term financial visibility.
Silence Therapeutics’ moat derives from its proprietary RNAi technology platform and clinical-stage pipeline, particularly the advancement of Divesiran. The company’s specialized expertise in RNAi therapeutics and ongoing clinical trial progress contribute to its competitive positioning in the biopharmaceutical sector. Strategic partnerships and capital raises support its development efforts.
• Clinical Development Risk: The success of RNAi therapeutics depends on clinical trial outcomes, regulatory approvals, and market acceptance, which remain uncertain.
• Financial Risk: Continued net losses and reliance on capital raises may impact financial stability if development timelines extend or costs increase.
• Cybersecurity Risk: Potential cybersecurity incidents could damage reputation, incur costs, or lead to legal liabilities despite governance oversight.
Business trends: Clinical advancement of RNAi therapeutics, notably Divesiran, and capital market activity including public offerings and acquisition interest.
Execution milestones: Achieving Phase 2 clinical goals, initiating Phase 3 trials, and maintaining strong liquidity and cybersecurity governance.
Key risks: Clinical trial uncertainties, ongoing net losses requiring capital, and cybersecurity vulnerabilities impacting operations and reputation.
High visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Silence Therapeutics plc is a biopharmaceutical company focused on RNA interference (RNAi) therapeutics development.
- The company reported third quarter 2026 financial results on November 13, 2026, including a net loss of $12.426 million and basic and diluted EPS of -$0.08 per share for the period ending September 30, 2026 [N1][S2].
- As of September 30, 2026, Silence Therapeutics held $247.659 million in cash and cash equivalents, with current assets of $269.576 million and current liabilities of $11.259 million, resulting in a strong current ratio of 23.94 and a cash ratio of 22 [S2].
- Revenue was reported as £5.3 million for the fiscal year ending December 31, 2022 [S1].
- The company’s lead RNAi therapeutic, Divesiran, met its primary goal in a Phase 2 polycythemia vera (PV) study and is set up for a Phase 3 PV trial [N7][N8].
- Silence Therapeutics announced a public offering worth $150 million in American Depositary Shares in August 2026 [N1].
- The company’s stock experienced significant volatility in 2026, including a 126% surge following an acquisition deal with Merck KGaA in October 2026 [N4], and a 28.8% decline over four weeks in mid-October 2026 [N5].
- The board of directors oversees cybersecurity risk management, with an experienced Head of IT responsible for implementing cybersecurity processes and incident response, including escalation to executive leadership and the audit and risk committee [S1].
- Risk factors disclosed include cybersecurity risks that could impact reputation and result in costs or legal actions [S1].
Generated 2026-11-14
- S1 | 2026-03-05 | 10-K
- S2 | 2026-11-12 | 10-Q
- N1 | 2026-11-13 | www.nasdaq.com | Silence Therapeutics plc Reports Third Quarter 2026 Financial Results | https://www.nasdaq.com/articles/silence-therapeutics-plc-reports-third-quarter-2026-financial-results
- N2 | 2026-10-20 | www.nasdaq.com | Does Silence Therapeutics (SLN) Have the Potential to Rally 82.84% as Wall Street Analysts Expect? | https://www.nasdaq.com/articles/does-silence-therapeutics-sln-have-potential-rally-8284-wall-street-analysts-expect
- N3 | 2026-10-19 | www.nasdaq.com | Biotech Stocks Rally: SLN Soars 125%, WORX Jumps 105%, IRON Gains 41% | https://www.nasdaq.com/articles/biotech-stocks-rally-sln-soars-125-worx-jumps-105-iron-gains-41
- N4 | 2026-10-19 | www.nasdaq.com | Silence Therapeutics Stock Soars 126% On Merck KGaA Acquisition Deal | https://www.nasdaq.com/articles/silence-therapeutics-stock-soars-126-merck-kgaa-acquisition-deal
- N5 | 2026-10-14 | www.nasdaq.com | Silence Therapeutics (SLN) Loses 28.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner | https://www.nasdaq.com/articles/silence-therapeutics-sln-loses-288-4-weeks-heres-why-trend-reversal-may-be-around-corner
- N6 | 2026-08-13 | www.nasdaq.com | Wall Street Analysts Predict a 140.06% Upside in Silence Therapeutics (SLN): Here's What You Should Know | https://www.nasdaq.com/articles/wall-street-analysts-predict-14006-upside-silence-therapeutics-sln-heres-what-you-should
- N7 | 2026-08-11 | www.nasdaq.com | Silence Therapeutics’ Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial | https://www.nasdaq.com/articles/silence-therapeutics-divesiran-hits-phase-ii-goal-sets-phase-iii-pv-trial
- N8 | 2026-08-10 | www.nasdaq.com | Silence Therapeutics Soars As Divesiran Meets Primary Goal In Phase 2 PV Study;Q2 Net Loss Narrows | https://www.nasdaq.com/articles/silence-therapeutics-soars-divesiran-meets-primary-goal-phase-2-pv-studyq2-net-loss
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


